Hairy Cell Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hairy cell leukemia. 3 active patents protecting 1 drugs from 0+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
3
Active US patents
73/100
Avg vulnerability
$700M
Annual revenue covered

Originators in Hairy Cell Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hairy cell leukemia. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Leustatin
CLADRIBINE
 — 3 73 $700M 2038-11-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12533408 Leustatin method of use 75 2041-09-10
12539329 Leustatin method of use 75 2041-09-10
10849919 Leustatin method of use 70 2038-11-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10849919 Leustatin method of use 70 2038-11-23
12533408 Leustatin method of use 75 2041-09-10
12539329 Leustatin method of use 75 2041-09-10

Related